1. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC (1988) c DNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85: 4934–4938
2. Prada M, Kettler R, Keller HH, Burkard WP(1988) RO 19–6327, a resersible, highly selective inhibitor of type B monoamine oxidase, completely devoid of tyramine-potentiating effects: comparison with selegiline. Neurol Neurobiol 42B: 359–363
3. Prada M, Keller HH, Kettler R (1989) Vergleich der neuen MAO-A-Hemmer Moclobemid und Toloxaton mit Tranylcypromin im Tierversuch: Bedeutung für die Praxis. In: Laux G, Riederer P (Hrsg) Neue selektive Monoaminoxidase-Hemmer in der Therapie depressiver Erkrankungen. Psychiat Prax [Sonderheft I] 16: 18–24
4. Denney RM, Patel NT, Fritz RR, Abell CW(1982) A monoclonal antibody elicited to human platelet monoamine oxidase. Isolation and specificity for human monoamine oxidase B but not A. Mol Pharmacol 22: 500–508
5. Dollery CT, Davies DS, Strolin-Benedetti M(1982) Clinical pharmacology of MD 780515, a selective and reversible MAO-A inhibitor. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase, basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 221–229